|
May 29
|
How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created
|
|
May 28
|
GLP-1 prescriptions for weight loss are shooting up, despite obstacles
|
|
May 28
|
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?
|
|
May 27
|
Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position”
|
|
May 27
|
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
|
|
May 27
|
3 Surprising Stocks That Have More Than Doubled in 2025
|
|
May 27
|
Why Novo Nordisk Stock Just Popped
|
|
May 27
|
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
|
|
May 24
|
Why Hims & Hers Health Stock (HIMS) Is Too Hot to Handle
|
|
May 23
|
European Equities Close Sharply Lower in Friday Trading; German Q1 GDP Expands 0.4% Sequentially
|
|
May 23
|
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
|
|
May 23
|
Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More
|
|
May 23
|
Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs
|
|
May 22
|
Bitcoin soars, Fannie Mae & Freddie Mac, Novo's GLP-1 discount
|
|
May 22
|
Novo Nordisk battles Wegovy copycats through discounted prices, legal threats
|
|
May 22
|
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
|
|
May 22
|
New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
|
|
May 22
|
Wegovy and Zepbound costs capped at $200 in new Evernorth programme
|
|
May 22
|
Evernorth reaches deals with Novo Nordisk, Eli Lilly to cap GLP-1 copays
|
|
May 19
|
Novo Nordisk (NVO) Slides After CEO Departure; Analyst Flags Deeper Strategic Concerns
|